Over the past decade, non-coding RNA-based therapeutics have proven as a great potential
for the development of targeted therapies for cancer and other diseases. The discovery of …

Lipid nanoparticles have attracted significant interests in the last two decades, and have
achieved tremendous clinical success since the first clinical approval of Doxil in 1995. At the …

Background Transthyretin amyloidosis, also called ATTR amyloidosis, is a life-threatening
disease characterized by progressive accumulation of misfolded transthyretin (TTR) protein …

There is growing need for a safe, efficient, specific and non-pathogenic means for delivery of
gene therapy materials. Nanomaterials for nucleic acid delivery offer an unprecedented …

In nanoparticle (NP)-mediated drug delivery, liposomes are the most widely used drug
carrier, and the only NP system currently approved by the FDA for clinical use, owing to their …

The objective of this manuscript is to provide quantitative insights into the tissue distribution
of nanoparticles. Published pharmacokinetics of nanoparticles in plasma, tumor and 13 …

Nanoparticles have revolutionized biomedicine especially in the field of drug delivery due to
their intriguing properties such as systemic stability, level of solubility, and target site …

Post‐transcriptional gene silencing targets and degrades mRNA transcripts, silencing the
expression of specific genes. RNA interference technology, using synthetic structurally well …

Nanoparticle‐based small interfering RNA (siRNA) therapy shows great promise for
glioblastoma (GBM). However, charge associated toxicity and limited blood–brain‐barrier …

It has been almost two decades since the first link between microRNAs and cancer was
established. In the ensuing years, this abundant class of short noncoding regulatory RNAs …